Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce Yet Another First Cycle FDA Approval for
Benzinga Milla Pharmaceuticals Inc., a subsidiary of the Alter Pharma Group, announced that it has received FDA approval for its generic version of Precedex, Dexmedetomidine Hydrochloride Injection 4mcg/ml in 50mL and 100mL, and plans to launch in the very near future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230609005336/en/
Dexmedetomidine Hydrochloride Injection is indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting. It should be administered by continuous infusion not to exceed 24 hours.
Dexmedetomidine Hydrochloride Injection 4mcg/ml in 50mL and 100mL is currently on FDA's Drug Shortages list. This latest approval of Dexmedetomidine Hydrochloride Injection will help reduce the recent supply issues for the product experienced in the U.S.
This achievement marks the second "First Cycle" Approval ANDA for Milla Pharmaceuticals Inc. and the Alter Pharma Group for the U.S. market, after their first "First Cycle" Approval ANDA for Sodium Acetate Injection 2MEQ/mL in the Summer of 2021, which was also an FDA Drug Shortage listed product. This new milestone also marks the approval of our second Paragraph IV Filing and the 5th ANDA approval for the Alter Pharma Group.
